Journal of Clinical Nephrology and Therapeutics

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
Reach Us +1 (202) 780-3397

Perspective - Journal of Clinical Nephrology and Therapeutics (2024) Volume 8, Issue 1

Advancements in clinical nephrology: Enhancing kidney health and patient care

Daniel Kim*

Department of Nephrology, Brigham and Women's Hospital, USA

*Corresponding Author:
Daniel Kim
Department of Nephrology, Brigham and Women's Hospital, USA
Brigham and Women's Hospital
USA
E-mail:daniel@kim.edu

Received:27-Jan-2024,Manuscript No. AACNT-24-129042; Editor assigned:01-Feb-2024,PreQC No. AACNT-24-129042(PQ); Reviewed:15-Feb-2024,QC No. AACNT-24-129042; Revised:22-Feb-2024,Manuscript No. AACNT-24-129042(R); Published:29-Feb-2024,DOI: 10.35841/aacnt-8.1.183

Citation: Kim D. Advancements in clinical nephrology: Enhancing kidney health and patient care. J Clin Nephrol Ther. 2024;8(1):183

Visit for more related articles at Journal of Clinical Nephrology and Therapeutics

Introduction

A crucial medical specialty that focuses on the identification, treatment, and management of kidney problems is clinical nephrology. Improvements in clinical nephrology over time have transformed our understanding and management of different kidney diseases, improving patient outcomes and quality of life. The purpose of this article is to examine the effects of current developments in clinical nephrology on kidney health and patient treatment.[1].

Early Diagnosis and Identification: The early identification and diagnosis of kidney illnesses is one of the main areas of advancement in clinical nephrology. Thanks to the advancements in imaging techniques and novel biomarkers, kidney problems can now be detected earlier by doctors, enabling prompt intervention and therapy. Biomarkers such urinary albumin-to-creatinine ratio, cystatin C, and serum creatinine have been invaluable tools in the diagnosis and monitoring of kidney function. Precision Medicine Approaches: Using precision medicine approaches is a major step forward in clinical nephrology. Nephrologists can now customise therapy regimens for individual patients, maximising therapeutic success and reducing side effects, by combining genetic, molecular, and clinical data. Among the tools that show promise for predicting drug reactions and helping patients with kidney illnesses choose their medications is pharmacogenomics testing.[2].

Therapy Modalities Innovations: The range of therapy options for renal illnesses has undergone substantial innovation in the last few years. The treatment of renal diseases has been considerably enhanced by these developments, which range from the creation of innovative immunosuppressive medications for kidney transplant recipients to improvements in dialysis technology. Options for home dialysis, such as hemodialysis and peritoneal dialysis, give patients more freedom and flexibility in managing their treatment. Furthermore, in clinical nephrology, patient-centered treatment has become increasingly important. In order to provide care that is specific to each patient's needs, clinicians are increasingly taking into account the goals, values, and preferences of their patients when making treatment decisions. The implementation of shared decision-making, patient education, and support programmes is crucial in enabling patients to take an active role in their healthcare and make well-informed decisions.[3].

Lastly, a distinguishing feature of contemporary clinical nephrology practice is the implementation of collaborative care models. Patients with kidney illnesses receive comprehensive care from multidisciplinary care teams, which are made up of nephrologists, nurses, dietitians, social workers, and other allied health professionals. Patients are guaranteed to receive integrated, holistic care that takes into account their social, emotional, and medical requirements thanks to this cooperative approach. In summary, developments in clinical nephrology have changed the way that kidney health and patient care are approached. Patients with renal illnesses now have considerably better outcomes thanks to breakthroughs in early identification, precision medicine, novel treatment modalities, and patient-centred care. To ensure that patients with kidney problems receive the best care possible, the profession of clinical nephrology will need to advance through ongoing research, innovation, and collaboration. Clinical nephrology is essential to managing the wide range of kidney problems, from the early diagnosis of chronic kidney disease to the dialysis and transplantation used to treat end-stage renal illness. Furthermore, the quality of care given to patients with renal illnesses has been significantly improved by the integration of multidisciplinary care teams, cutting-edge technologies, and evidence-based Compared to dialysis, kidney transplantation is thought to be the best course of action for eligible individuals with end-stage renal disease (ESRD), as it improves survival and quality of life. Improved long-term graft results, a larger donor pool, and less ischemia-reperfusion harm are the main goals of recent advancements in kidney transplantation. Desensitisation procedures, paired kidney exchange programmes, and machine perfusion technologies are examples of innovations that have increased access to transplantation and enhanced outcomes for transplant recipients.[4].

In the future, more study, cooperation, and creativity will be needed to develop the discipline of clinical nephrology. Nephrologists have a significant influence on the lives of people with kidney illnesses through fighting for fair access to treatment, encouraging preventive measures, and aiming for excellence in patient care. For patients with renal diseases, clinical nephrology essentially acts as a ray of hope, providing individualised innovative treatments, and the promise of improved health and well-being. With dedication, perseverance, and a commitment to excellence, the field of clinical nephrology will continue to pave the way towards a brighter future for kidney health.[5].

References

References

  1. Ohkuni H, Friedman J. Immunological studies of post-streptococcal sequelae: serological studies with an extracellular protein associated with nephritogenic streptococci. Clin Exp Immunol. 1983;54(1):185.

    2. Indexed at, Google Scholar, Cross ref

     

  2. Vosti KL, Johnson RH, Dillon MF. Further characterization of purified fractions of M protein from a strain of group A, type 12 Streptococcus. J Immun. 1971;107(1):104-14.

    3. Indexed at, Google Scholar, Cross ref

     

  3. Worawichawong S, Girard L. Immunoglobulin A–dominant postinfectious glomerulonephritis: frequent occurrence in nondiabetic patients with Staphylococcus aureus infection. Hum pathol. 2011;42(2):279-84.

    4. Indexed at, Google Scholar, Cross ref

     

  4. Pola E, Logroscino. Onset of Berger disease after Staphylococcus aureus infection: septic arthritis after anterior cruciate ligament reconstruction. Arthrosc - J Arthrosc Relat Surg. 2003 Apr 1;19(4):1-3.

    5. Indexed at, Google Scholar, Cross ref

     

  5. Nasr SH, Markowitz GS, Whelan JD, et al. IgA-dominant acute poststaphylococcal glomerulonephritis complicating diabetic nephropathy. Hum Pathol. 2003 ;34(12):1235-41.

    6. Indexed at, Google Scholar, Cross ref

     

  6. King MD, Humphrey BJ, Wang YF, et al. Emergence of community-acquired methicillin-resistant Staphylococcus aureus USA 300 clone as the predominant cause of skin and soft-tissue infections. Ann Intern Med. 2006;144(5):309-17.

    7. Indexed at, Google Scholar, Cross ref 

     

  7. Tattevin P, Diep BA, Jula M, et al. Methicillin-resistant Staphylococcus aureus USA300 clone in long-term care facility. Emerg Infect Dis. 2009;15(6):953.

    8. Indexed at, Google Scholar, Cross ref 

     

  8. DeLeo FR, Otto M, Kreiswirth BN, et al. Community-associated meticillin-resistant Staphylococcus aureus. TheLancet. 2010;375(9725):1557-68.

    9. Indexed at, Google Scholar, Cross ref 

     

  9. Jackson KA. Invasive methicillin-resistant Staphylococcus aureus infections among persons who inject drugs—six sites, 2005–2016. MMWR. Morb Mortal Wkly Rep. 2018;67

    10. Indexed at, Google Scholar, Cross ref

     

  10. Pola E, Logroscino. Onset of Berger disease after Staphylococcus aureus infection: septic arthritis after anterior cruciate ligament reconstruction. Arthrosc - J Arthrosc Relat Surg. 2003 Apr 1;19(4):1-3.

    11. Indexed at, Google Scholar, Cross ref

Get the App